XTLB Stock Analysis: Buy, Sell, or Hold?
XTLB - XTL Biopharmaceuticals Ltd. American Depositary Shares
$2.63
-0.15 (-5.57%)
▼
5d:
+0.97%
30d:
-10.71%
90d:
+4.59%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When XTLB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: XTLB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: XTLB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: XTLB is currently trading at $2.63, which is considered oversold relative to its 30-day fair value range of $2.73 to $2.98.
Technical Outlook: Technically, XTLB is showing sideways momentum. The price is currently testing key support at $2.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: XTLB scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+1042.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XTLB is showing sideways momentum. The price is currently testing key support at $2.55. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: XTLB scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+1042.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.73 -
$2.98
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 1042.8% below Wall St target ($30.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.73 -
$2.98
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.55
Resistance Level
$3.52
Current Trend
Sideways
Technical data as of
Aug 24, 2026
Fundamental Context
Wall Street Target
$30.00
(+1042.8%)
Earnings Growth (YoY)
-76.0%
Share & Embed Analysis
Last updated: August 24, 2026 6:04 PM ET
Data refreshes hourly during market hours. Next update: 7:04 PM
Data refreshes hourly during market hours. Next update: 7:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XTLB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 65 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 38 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 39 SELL |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 34 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 41 HOLD |